1 |
Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2;769-776, 2001
|
2 |
Frame S, Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359;1-16, 2001
DOI
ScienceOn
|
3 |
Woodgett JR: Judging a protein by more than its name: GSK-3. Sci STKE 2001;re12, 2001
|
4 |
Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMPdependent protein kinase and phosphorylase kinase. Eur J Biochem 107;519-527, 1980
|
5 |
Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR: Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275;1930-1934, 1997
DOI
ScienceOn
|
6 |
El Jamali A, Freund C, Rechner C, Scheidereit C, Dietz R, Bergmann MW: Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3 beta. FASEB J 18;1096-1098, 2004
|
7 |
Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr: The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8;25-33, 2005
DOI
ScienceOn
|
8 |
Gregory MA, Qi Y, Hann SR: Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278;51606-51612, 2003
DOI
ScienceOn
|
9 |
Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2; 339-345, 2003
|
10 |
Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE, Zinker BA, Trevillyan JM, Ulich RG, Jirousek MR, Rondinone CM: Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52;21-28, 2003
DOI
ScienceOn
|
11 |
Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma ST, Reeder JW, Samuels I, Slabiak T, Wagman AS, Hammond ME, Harrison SD: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52;588-595, 2003
DOI
ScienceOn
|
12 |
Martinez A, Perez DI: GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15;181-191, 2008
DOI
|
13 |
Beaulieu JM, Gainetdinov RR, Caron MG: Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49;327-347, 2009
DOI
ScienceOn
|
14 |
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126;955-968, 2006
DOI
ScienceOn
|
15 |
Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor- mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6;777- 784, 2005
|
16 |
Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB: IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24;563-574, 2006
DOI
ScienceOn
|
17 |
Wada A: GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 14;1558- 1570, 2009
|
18 |
Rehani K, Wang H, Garcia CA, Kinane DF, Martin M: Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol 182;547-553, 2009
DOI
|
19 |
Beurel E, Jope RS: Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharide- induced IL-6 production in RAW264.7 cells. Cell Signal 21;978-985, 2009
DOI
ScienceOn
|
20 |
Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3;479-487, 2004
DOI
ScienceOn
|
21 |
Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN: GSK3beta: role in therapeutic landscape and development of modulators. Br J Phamacol 160;1-19, 2010
DOI
ScienceOn
|
22 |
Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 305;974-980, 2003
DOI
ScienceOn
|
23 |
Fischer PM: CDK versus GSK-3 inhibition: a purple haze no longer? Chem Biol 10;1144-1146, 2003
DOI
ScienceOn
|
24 |
Phiel CJ, Klein PS: Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41;789-813, 2001
DOI
ScienceOn
|
25 |
Sawa M: Strategies for the design of selective protein kinase inhibitors. Mini Rev Med Chem 8;1291-1297, 2008
DOI
ScienceOn
|
26 |
Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105;721-732, 2001
DOI
ScienceOn
|
27 |
Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee HJ, Jeong D, Kim N, Choi Y, Lee SY: Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 119;813-825, 2009
DOI
ScienceOn
|
28 |
Frame S, Cohen P, Biondi RM: A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7;1321- 1327, 2001
DOI
ScienceOn
|
29 |
ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J: Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 8;593-596, 2001
DOI
ScienceOn
|
30 |
Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, Kim YE, Shin JA, Park CS, Park JW, Park TK, Lee JH, Seo BF, Kim KD, Kim ES, Lee DH, Lee SK, Lee SK: Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 12;574-579, 2006
DOI
ScienceOn
|
31 |
Beurel E, Michalek SM, Jope RS: Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 31;24-31, 2010
DOI
ScienceOn
|
32 |
Jope RS, Yuskaitis CJ, Beurel E: Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32;577-595, 2007
DOI
ScienceOn
|
33 |
Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A: Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156;885-898, 2009
DOI
ScienceOn
|
34 |
Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, Smith DG, Reith AD: The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure 9;1143-1152, 2001
DOI
ScienceOn
|
35 |
Doble BW, Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116;1175-1186, 2003
DOI
ScienceOn
|
36 |
Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ: Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3;1009-1013, 2001
DOI
ScienceOn
|
37 |
Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, Michiels C: Regulation of hypoxia-inducible factor- 1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278;31277- 31285, 2003
DOI
ScienceOn
|
38 |
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378;785-789, 1995
DOI
ScienceOn
|
39 |
Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 305;974-980, 2003
DOI
ScienceOn
|
40 |
Sato AK, Viswanathan M, Kent RB, Wood CR: Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17;638-642, 2006
DOI
ScienceOn
|